Skip to Content
Merck
CN
  • Phage tail-like particles kill Clostridium difficile and represent an alternative to conventional antibiotics.

Phage tail-like particles kill Clostridium difficile and represent an alternative to conventional antibiotics.

Surgery (2014-07-26)
William Sangster, John P Hegarty, David B Stewart
ABSTRACT

Current Clostridium difficile infection (CDI) antibiotic regimens have become increasingly ineffective at achieving cure and preventing recurrence. A recently developed alternative to conventional antibiotics are phage tail-like particles (PTLPs), which are proteins that are morphologically similar to bacteriophages and are produced by C difficile. This study examines the in vitro killing spectrum of a previously unreported PTLP isolated from a clinical isolate of C difficile. Using patient-derived samples from an institutional review board-approved C difficile tissue bank, a ribotype 078 C difficile isolate was anaerobically incubated on blood agar plates that were preswabbed with norfloxacin to induce the production of PTLPs. Concentrated PTLP populations were confirmed using transmission electron microscopy. Using a standard lawn spot approach, bactericidal activity was assessed as indicated by a clearing within the bacterial lawn. The PTLP genomic cluster was also fully sequenced and open reading frames were annotated according to predicted function. PTLPs were assessed using 64 patient-derived C difficile isolates of varying ribotypes. PTLPs demonstrated complete bactericidal activity in 21 of 25 ribotype 027 isolates with partial activity in 2 of the 25. Complete bactericidal activity was not demonstrated against any other ribotype or non-difficile bacteria, suggesting a species and ribotype specificity. Functional genes, which may be necessary for killing, were identified within the PTLP genetic locus. PTLPs demonstrate capability in eradicating C difficile in vitro, and with further development, may represent an organism-specific, microbiome-sparing therapy for CDI.

MATERIALS
Product Number
Brand
Product Description

Norfloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard
Supelco
Norfloxacin, analytical standard, ≥98% (TLC)
Supelco
Norfloxacin, VETRANAL®, analytical standard
Sigma-Aldrich
2-Phenylethanol, ≥99.0% (GC)
Norfloxacin, European Pharmacopoeia (EP) Reference Standard
Supelco
Phenylethyl Alcohol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Phenethyl alcohol, ≥99%, FCC, FG
Sigma-Aldrich
Phenethyl alcohol, natural, ≥99%, FCC, FG
Norfloxacin for peak identification, European Pharmacopoeia (EP) Reference Standard